Vaccines and Global Health: The Week in Review has expanded its coverage of new reports, books, research and analysis published independent of the journal channel covered in Journal Watch below. Our interests span immunization and vaccines, as well as global public health, health governance, and associated themes. If you would like to suggest content to be included in this service, please contact David Curry at: firstname.lastname@example.org
TRACKING PROGRESS TO ADDRESS AMR
AMR Industry Alliance – amrindustryalliance.org
JANUARY 2018 :: 108 pages
The AMR Industry Alliance launched its first progress report on 18 January 2018. This report shows the commitment of the life sciences industry to tackle the public health threat of antimicrobial resistance (AMR). The Alliance brings together over 100 biotech, diagnostics, generics and research-based biopharmaceutical companies and trade associations from 20 countries.
The report was compiled by the consultancy SustainAbility. The data and case studies collected in the Alliance report provide unique insights into the practical steps Alliance’s members are taking to respond to AMR in the areas of research and science, access, appropriate use, and the environment.
The report presents data on AMR-relevant products, including therapeutic agents or technologies that have the potential to treat or prevent infectious diseases and/or combat resistance, including but not limited to antibiotics, vaccines, diagnostics, and novel approaches to address AMR.
[Excerpt p. 31]
AMR-RELEVANT VACCINE CANDIDATES IN DEVELOPMENT
Vaccines hold significant promise in the field of AMR. Vaccines targeting bacteria directly limit
infections and therefore the use of antibiotics, which would be the recommended treatment.
Vaccines targeting viruses can also reduce antibiotic use, by preventing viral infections that
might otherwise be inappropriately treated with antibiotics.
Six responding companies are involved in AMR-relevant vaccine R&D, with 13 candidates in
active development in the last five years… The Beam Alliance reported other preventive approaches – including immunomodulating, antivirulence and decontamination/decolonization – under development by SMEs including Antabio, Arsanis, BioVersys, BioFilmControl, Centauri Therapeutics, DaVolterra, Eligo Bioscience, Helperby, Maat Pharma, Mutabilis and Quretech.
18 January 2018
Report shows life sciences industry alliance is taking action to curb antimicrobial resistance, with more to come
The new AMR Industry Alliance of more than 100 biotech, diagnostics, generics and research-based biopharmaceutical companies and trade associations launches its first progress report today. The report measures action taken in four areas: research and science, access, appropriate use, and the environment.
:: In 2016, the report shows that 22 Alliance companies invested at least USD 2 billion in R&D dedicated to AMR-related products. The funds cover costs for early-stage R&D, exploring new product classes, ten antibiotics in late-stage clinical development, 13 clinical bacterial vaccine candidates, 18 AMR-relevant diagnostic products, and other preventive therapies.
:: More than two out of three Alliance companies surveyed with marketed AMR products, have strategies, policies or plans in place to improve access to their AMR-relevant products.
: The Alliance is appealing to policy makers to draw from the evidence provided in this report, and invites stakeholders to work more systematically with the life sciences industry, to find sustainable solutions to tackling antimicrobial resistance.
:: The Alliance plans to give further impetus to industry efforts to curb AMR by increasing levels of response in the next progress report in 2020.